Mangoceuticals enters licensing deal for Kyzatrex® testosterone capsules with Marius Pharmaceuticals

MANGOCEUTICALS, INC.

Issued 100,000 restricted shares to Marius for non-exclusive license to market Kyzatrex® on MangoRx telehealth platform.
Two-year initial term; renews automatically if MangoRx maintains at least 2,500 monthly Kyzatrex patients.
Marius can terminate without cause on 60 days' notice, or if 30% of patient milestone not met within 6 months of launch by Jan 31, 2024.
MangoRx agrees not to market competing testosterone undecanoate products during term and 12 months after.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MANGOCEUTICALS, INC. entered into Marius Agreement with Marius Pharmaceuticals, LLC valued at 100,000 shares of our restricted common stock (effective 2023-12-10).

Action: entry
Agreement: license
Counterparty: Marius Pharmaceuticals, LLC
Value: 100,000 shares of our restricted common stock
Effective: 2023-12-10

Exact text from the filing

On December 10, 2023, we entered into a Marketing Agreement with Marius Pharmaceuticals, LLC (“ Marius ”) allowing us the use of the trademark “Kyzatrex®” oral testosterone undecanoate softgel capsules

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-044387

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.